-
Posted by
Two Blokes Fri at 12:00 PM -
Filed in
Stock
-
2 views
Bagsværd, Denmark, 25 July 2025 – Novo Nordisk today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an update of the Alhemo\u00ae (concizumab) label to include the treatment of severe haemophilia A and moderate or severe haemophilia B without inhibitors.
